Galderma cited GLP-1 weight loss drug adoption (semaglutide, tirzepatide) as a revenue tailwind, with patients seeking facial volume restoration and skin tightening to address "Ozempic face"—the hollowed appearance and skin laxity that can result from rapid weight loss. The phenomenon is driving incremental demand for fillers, toxins, and RF microneedling treatments.
Market
Galderma Capitalizes on GLP-1 Weight Loss Trend; 'Ozempic Face' Drives Filler and Toxin Demand
Rapid weight loss from semaglutide and tirzepatide is creating new patient demand for facial volume restoration and skin tightening.
GLP-1 weight loss is creating a new patient cohort seeking facial volume restoration and skin tightening.
For practices, this is a concrete new patient acquisition angle. GLP-1 users represent a defined, growing cohort with disposable income and active engagement in their appearance. Practices should consider targeted marketing to weight-loss clinics, primary-care practices prescribing GLP-1s, and online weight-loss platforms. The clinical opportunity spans multiple modalities: HA fillers for cheek and temple volume, biostimulators (PLLA, CaHA) for longer-term collagen induction, and RF microneedling for skin quality. Practices with strong filler and energy-device capabilities are best positioned to capture this segment.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.